1. Search Result
Search Result
Results for "

phosphoribosyltransferase

" in MedChemExpress (MCE) Product Catalog:

39

Inhibitors & Agonists

5

Natural
Products

9

Recombinant Proteins

6

Isotope-Labeled Compounds

4

Antibodies

1

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-128700A

    Endogenous Metabolite Metabolic Disease
    Nicotinic acid mononucleotide triethylamine is formed from nicotinic acid (NA) via the nicotinic acid phosphoribosyltransferase in the biosynthesis of NAD +. Nicotinate mononucleotide triethylamine is a substrate for nicotinamide mononucleotide/Nicotinic acid mononucleotide adenylyltransferase .
    Nicotinic acid mononucleotide triethylamine
  • HY-N9941

    Endogenous Metabolite Metabolic Disease
    2,8-Dihydroxyadenine, an endogenous metabolite, can cause the formation of urinary crystals and kidney stones. 2,8-Dihydroxyadenine can be used to diagnose adenine phosphoribosyltransferase (APRT) deficiency .
    2,8-Dihydroxyadenine
  • HY-N8060A

    Orotidine monophosphate trisodium; Orotidylic acid trisodium

    Endogenous Metabolite DNA/RNA Synthesis Metabolic Disease
    Orotidine 5'-monophosphate trisodium is a pyrimidine nucleotide. Orotidine 5'-monophosphate trisodium is synthesized via the de novo synthesis pathway for DNA synthesis in a large number of microorganisms including M. tuberculosis, S. cerevisiae, S. typhimurium and P. falciparum to name a few. The synthesis of orotidine 5'-monophosphate trisodium uses phosphoribosyl pyrophosphate (PRPP) and orotic acid (OA) as the substrates catalyzed by orotate phosphoribosyltransferase (OPRT) .
    Orotidine 5′-monophosphate trisodium
  • HY-119413

    Endogenous Metabolite Neurological Disease
    9-Ethyladenine is a partially effective inhibitor of APRT (adenine phosphoribosyltransferase) .
    9-Ethyladenine
  • HY-50876
    Daporinad
    Maximum Cited Publications
    46 Publications Verification

    FK866; APO866

    NAMPT Autophagy Cancer
    Daporinad (FK866) is an effective inhibitor of nicotinamide phosphoribosyltransferase (NMPRTase; Nampt) with an IC50 of 0.09 nM.
    Daporinad
  • HY-148815

    NAMPT Neurological Disease
    Nampt activator-1 (compound 1) is a potent Nicotinamide phosphoribosyltransferase (NAMPT) activator, with EC50 of 3.3-3.7 μM .
    Nampt activator-1
  • HY-128700
    Nicotinic acid mononucleotide
    1 Publications Verification

    Endogenous Metabolite Metabolic Disease
    Nicotinic acid mononucleotide (NAMN) is formed from nicotinic acid (NA) via the nicotinic acid phosphoribosyltransferase in the biosynthesis of NAD +. Nicotinate mononucleotide is a substrate for nicotinamide mononucleotide/Nicotinic acid mononucleotide adenylyltransferase .
    Nicotinic acid mononucleotide
  • HY-12793
    Padnarsertib
    2 Publications Verification

    KPT-9274

    PAK NAMPT Cancer
    Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC50s of <100 nM and 120 nM, respectively .
    Padnarsertib
  • HY-144294

    Parasite Infection
    Purine phosphoribosyltransferase-IN-1 (Compound (S,R)-48) is a potent inhibitor of the Plasmodium falciparum (Pf), P. vivax (Pv) and Trypanosoma brucei (Tbr) 6-oxopurine purine phosphoribosyltransferases (PRTs), with Ki values of 50, 20, and 2 nM, respectively .
    Purine phosphoribosyltransferase-IN-1
  • HY-144296

    Parasite Infection
    Purine phosphoribosyltransferase-IN-2 is a potent inhibitor of the Plasmodium falciparum ((Pf)), Plasmodium vivax ((Pv)) and Trypanosoma brucei ((Tbr)) 6-oxopurine phosphoribosyltransferase (PRT), with Kis of 30, 20 and 2 nM, respectively .
    Purine phosphoribosyltransferase-IN-2
  • HY-101280A

    NAMPT Cancer
    LB-60-OF61 hydrochloride is a potent NAMPT (nicotinamide phosphoribosyltransferase) inhibitor. LB-60-OF61 hydrochloride is a cytotoxic compound with a selectivity towards MYC overexpressing cell lines .
    LB-60-OF61 hydrochloride
  • HY-157421

    NAMPT Others
    Nampt activator-4 is a positive allosteric modulator (N-PAM) of nicotinamide phosphoribosyltransferase (NAMPT) with an EC50 of 0.058 μM. Nampt activator-4 can enhance the nicotinamide adenine dinucleotide (NAD +) in cells .
    Nampt activator-4
  • HY-163499

    NAMPT Cancer
    NAMPT activator-7 (Compound 232) is an activator for nicotinamide phosphoribosyltransferase (NAMPT), with EC50 < 0.5 μM. NAMPT activator-7 activates NAMPT in cells U2OS with cellular EC50 of < 0.5 μM .
    NAMPT activator-7
  • HY-108701

    NAMPT HDAC Autophagy Apoptosis Cancer
    Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death .
    Nampt-IN-3
  • HY-163500

    NAMPT Cancer
    NAMPT activator-8 (Compound 278) is an activator for nicotinamide phosphoribosyltransferase (NAMPT), with EC50 < 0.5 μM. NAMPT activator-8 activates NAMPT in cells U2OS with cellular EC50 of < 0.5 μM .
    NAMPT activator-8
  • HY-10079
    CHS-828
    3 Publications Verification

    GMX1778

    NAMPT Apoptosis Cancer
    CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD + and exhibits a potent anticancer activity .
    CHS-828
  • HY-10079A

    GMX1778 (nicotinate)

    NAMPT Apoptosis Cancer
    CHS-828 nicotinate is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 nicotinate (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD + and exhibits a potent anticancer activity .
    CHS-828 (nicotinate)
  • HY-122502

    Pirazofurin

    DNA/RNA Synthesis Antibiotic Influenza Virus HIV SARS-CoV Infection Cancer
    Pyrazofurin is an antitumor pyrimidine nucleoside analogue and a orotate-phosphoribosyltransferase inhibitor. Pyrazofurin inhibits cell proliferation and intracellular DNA synthesis by inhibiting uridine 5'-phosphate synthase. Pyrazofurin is also an antibiotic with a broad spectrum of antiviral activity .
    Pyrazofurin
  • HY-F0004
    β-Nicotinamide mononucleotide
    15+ Cited Publications

    β-NM; NMN

    Endogenous Metabolite Neurological Disease Cancer
    β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD + intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    β-Nicotinamide mononucleotide
  • HY-130606

    NAMPT Cytochrome P450 Cancer
    Nampt-IN-5 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-5 also inhibits CYP3A4 activity and has cellular IC50s of 0.7 nM and 3.9 nM against A2780 and COR-L23, respectively .
    Nampt-IN-5
  • HY-159015

    PROTACs Cancer
    SIAIS630120-NC is a negative control for NAMPT (nicotinamide phosphoribosyltransferase) degrader SIAIS630120 (Sturcture Note:(Blue: Cereblon ligand Thalidomide (HY-14658) analogue (HY-138793), Black: linker;Pink: Nampt inhibitor FK866 (HY-50876)) .
    SIAIS630120-NC
  • HY-147656

    ATTECs NAMPT Autophagy Cancer
    NAMPT degrader-1 (Compound A3), an autophagosome-tethering compound (ATTEC), is an nicotinamide phosphoribosyltransferase (NAMPT) degrader with an IC50 of 0.023 μM. NAMPT degrader-1 significantly induces the degradation of NAMPT through the autophagy-lysosomal pathway and shows excellent cellular antitumor potency .
    NAMPT degrader-1
  • HY-159016

    PROTACs Cancer
    SIAIS630121-NC is a negative control for NAMPT (nicotinamide phosphoribosyltransferase) degrader SIAIS630121(Sturcture Note:(Blue: Cereblon ligand Thalidomide (HY-14658) analogue (HY-138793), Black: linker;Pink: Nampt inhibitor FK866 (HY-50876)) .
    SIAIS630121-NC
  • HY-147193

    NAMPT Cancer
    Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC50s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .
    Nampt-IN-10 TFA
  • HY-147193A

    NAMPT Cancer
    Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC50 values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .
    Nampt-IN-10 trihydrochloride
  • HY-159009

    NAMPT Ligands for Target Protein for PROTAC Cancer
    MS7 is a potent inhibitor of nicotinamide phosphoribosyltransferase (NAMPT). NAMPT is overexpressed in many cancer cells to meet the continuous replenishment of NAD + required for rapid proliferation. MS7, as a NAMPT target protein ligand, can be used to synthesize PROTAC A7, which is an effective NAMPT degrader. MS7 can be used in cancer research .
    MS7
  • HY-10079R

    GMX1778 (Standard)

    Reference Standards NAMPT Apoptosis Cancer
    CHS-828 (Standard) is the analytical standard of CHS-828. This product is intended for research and analytical applications. CHS-828 (GMX1778) is a competitive inhibitor of nicotinamide phosphoribosyltransferase (NAMPT), with an IC50 less than 25 nM. CHS-828 (GMX1778) exerts a cytotoxic effect by decreasing the cellular level of NAD+ and exhibits a potent anticancer activity .
    CHS-828 (Standard)
  • HY-14373

    ZM 242421

    NAMPT Cancer
    CB30865 (ZM 242421) is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with potent cytotoxicity. CB30865 is highly potent against a variety of human tumour cell lines (IC50 values in the 1-10 nM range) . CB30865 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CB30865
  • HY-F0004S

    β-NM-d4; NMN-d4

    Endogenous Metabolite Neurological Disease Cancer
    β-Nicotinamide mononucleotide-d4 is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity .
    β-Nicotinamide mononucleotide-d4
  • HY-126255

    NAMPT Metabolic Disease
    SBI-797812 is an orally active nicotinamide phosphoribosyltransferase (NAMPT) activator. SBI-797812 shifts NAMPT to NMN formation, increases NAMPT affinity for ATP, stabilizes phosphorylated NAMPT, promotes consumption of the pyrophosphate by-product, and blunts feedback inhibition by NAD +. SBI-797812 increases intracellular nicotinamide mononucleotide (NMN) and elevates liver NAD + in mice .
    SBI-797812
  • HY-163280

    NAMPT Neurological Disease
    JGB-1-155 is a positive allosteric modulators (N-PAMs), which enhances the activity of nicotinamide phosphoribosyltransferase NAMPT with EC50 of 3.29 μM. JGB-1-155 counteracts the oxidative stress, through upregulating the NAD + in THP-1 human monocytes. JGB-1-155 attenuates TNFα-induced ROS in HT-22 cells .
    JGB-1-155
  • HY-162269

    NAMPT Neurological Disease
    Nampt activator-5 (compound C8) is a potent nicotinamide phosphoribosyltransferase (NAMPT) activator with a KD value of 6.19 µM. Nampt activator-5 shows a cellular antisenescence effect. Nampt activator-5 promotes the production of NAD + in the brain and reduces the expression of age-related markers and secretory phenotypes. Nampt activator-5 has the potential for the research of age-related diseases .
    Nampt activator-5
  • HY-158323

    Parasite Infection Cancer
    HGPRT/TBrHGPRT1-IN-1 (Compound 5) is a selective inhibitor targeting human hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and Trypanosoma bruce HGPRT1 (TBrHGPRT1) (both Ki=3 nM). HGPRT/TBrHGPRT1-IN-1 ultimately results in decreased cell growth. HGPRT/TBrHGPRT1-IN-1 is primarily used in the research of infectious diseases and cancer .
    HGPRT/TBrHGPRT1-IN-1
  • HY-N5134S1

    5'-GMP-13C10 dilithium; 5'-guanosine monophosphate-13C10 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    5'-Guanylic acid- 13C10 (5'-GMP- 13C10 dilithium; 5'-guanosine monophosphate- 13C10) dilithium is 13C-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
    5'-Guanylic acid-13C10 dilithium
  • HY-N5134S3

    5'-GMP-d12 dilithium; 5'-guanosine monophosphate-d12 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    5'-Guanylic acid-d12 (5'-GMP-d12 dilithium; 5'-guanosine monophosphate-d12) dilithium is deuterium labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
    5'-Guanylic acid-d12 dilithium
  • HY-158319

    Apoptosis Isocitrate Dehydrogenase (IDH) NAMPT Cancer
    Mutant IDH1/NAMPT-IN-1 (Compound 23h) is a dual inhibitor of mutant isocitrate dehydrogenase 1 (mutant IDH1) (IC50=14.93 nM) and nicotinamide phosphoribosyltransferase (NAMPT) (IC50=12.56 nM). Mutant IDH1/NAMPT-IN-1 can induce apoptosis. Mutant IDH1/NAMPT-IN-1 crosses the blood-brain barrier effectively .
    Mutant IDH1/NAMPT-IN-1
  • HY-N5134S2

    5'-GMP-15N5 dilithium; 5'-guanosine monophosphate-15N5 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    5'-Guanylic acid- 15N5 (5'-GMP- 15N5 dilithium; 5'-guanosine monophosphate- 15N5) dilithium is 15N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
    5'-Guanylic acid-15N5 dilithium
  • HY-N5134S5

    5'-GMP-13C10,15N5 dilithium; 5'-guanosine monophosphate-13C10,15N5 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    5'-Guanylic acid- 13C10, 15N5 (5'-GMP- 13C10, 15N5 dilithium; 5'-guanosine monophosphate- 13C10, 15N5) dilithium is 13C and 15N-labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
    5'-Guanylic acid-13C10,15N5 dilithium
  • HY-N5134S4

    5'-GMP-15N5,d12 dilithium; 5'-guanosine monophosphate-15N5,d12 dilithium

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    5'-Guanylic acid- 15N5,d12 (5'-GMP- 15N5,d12 dilithium; 5'-guanosine monophosphate- 15N5,d12) dilithium is deuterium and 15N labeled 5'-Guanylic acid (HY-N5134). 5'-Guanylic acid (5'-GMP) is involved in several metabolic disorders, including the AICA-ribosiduria pathway, adenosine deaminase deficiency, adenine phosphoribosyltransferase deficiency (aprt), and the 2-hydroxyglutric aciduria pathway.
    5'-Guanylic acid-15N5,d12 dilithium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: